Literature DB >> 20139276

Complement component C3 binds to activated normal platelets without preceding proteolytic activation and promotes binding to complement receptor 1.

Osama A Hamad1, Per H Nilsson, Diana Wouters, John D Lambris, Kristina N Ekdahl, Bo Nilsson.   

Abstract

It has been reported that complement is activated on the surface of activated platelets, despite the presence of multiple regulators of complement activation. To reinvestigate the mechanisms by which activated platelets bind to complement components, the presence of complement proteins on the surfaces of nonactivated and thrombin receptor-activating peptide-activated platelets was analyzed by flow cytometry and Western blot analyses. C1q, C4, C3, and C9 were found to bind to thrombin receptor-activating peptide-activated platelets in lepirudin-anticoagulated platelet-rich plasma (PRP) and whole blood. However, inhibiting complement activation at the C1q or C3 level did not block the binding of C3 to activated platelets. Diluting PRP and chelating divalent cations also had no effect, further indicating that the deposition of complement components was independent of complement activation. Furthermore, washed, activated platelets bound added C1q and C3 to the same extent as platelets in PRP. The use of mAbs against different forms of C3 demonstrated that the bound C3 consisted of C3(H(2)O). Furthermore, exogenously added soluble complement receptor 1 was shown to bind to this form of platelet-bound C3. These observations indicate that there is no complement activation on the surface of platelets under physiological conditions. This situation is in direct contrast to a number of pathological conditions in which regulators of complement activation are lacking and thrombocytopenia and thrombotic disease are the ultimate result. However, the generation of C3(H(2)O) represents nonproteolytic activation of C3 and after factor I cleavage may act as a ligand for receptor binding.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20139276      PMCID: PMC2953618          DOI: 10.4049/jimmunol.0902810

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  41 in total

1.  Complexes between C1q and C3 or C4: novel and specific markers for classical complement pathway activation.

Authors:  Diana Wouters; Hans D Wiessenberg; Margreet Hart; Peter Bruins; Alexandre Voskuyl; Mohamed R Daha; C Erik Hack
Journal:  J Immunol Methods       Date:  2005-03       Impact factor: 2.303

Review 2.  Platelets in sepsis.

Authors:  Marcel Levi
Journal:  Hematology       Date:  2005       Impact factor: 2.269

3.  Complement activation in acute coronary syndromes.

Authors:  Kenan Iltumur; Aziz Karabulut; Gülten Toprak; Nizamettin Toprak
Journal:  APMIS       Date:  2005-03       Impact factor: 3.205

4.  Structures of complement component C3 provide insights into the function and evolution of immunity.

Authors:  Bert J C Janssen; Eric G Huizinga; Hans C A Raaijmakers; Anja Roos; Mohamed R Daha; Kristina Nilsson-Ekdahl; Bo Nilsson; Piet Gros
Journal:  Nature       Date:  2005-09-22       Impact factor: 49.962

5.  Blood platelets activate the classical pathway of human complement.

Authors:  E I B Peerschke; W Yin; S E Grigg; B Ghebrehiwet
Journal:  J Thromb Haemost       Date:  2006-09       Impact factor: 5.824

6.  Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin.

Authors:  Madan Katragadda; Paola Magotti; Georgia Sfyroera; John D Lambris
Journal:  J Med Chem       Date:  2006-07-27       Impact factor: 7.446

7.  The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb).

Authors:  Fredrik Bexborn; Per Ola Andersson; Hui Chen; Bo Nilsson; Kristina N Ekdahl
Journal:  Mol Immunol       Date:  2007-12-21       Impact factor: 4.407

8.  Evidence that complement protein C1q interacts with C-reactive protein through its globular head region.

Authors:  Fabian D G McGrath; Mieke C Brouwer; Gérard J Arlaud; Mohamed R Daha; C Erik Hack; Anja Roos
Journal:  J Immunol       Date:  2006-03-01       Impact factor: 5.422

9.  Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets.

Authors:  O A Hamad; K N Ekdahl; P H Nilsson; J Andersson; P Magotti; J D Lambris; B Nilsson
Journal:  J Thromb Haemost       Date:  2008-05-22       Impact factor: 5.824

10.  Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation.

Authors:  Anne-lie Ståhl; Fariba Vaziri-Sani; Stefan Heinen; Ann-Charlotte Kristoffersson; Karl-Henrik Gydell; Reem Raafat; Alberto Gutierrez; Ortraud Beringer; Peter F Zipfel; Diana Karpman
Journal:  Blood       Date:  2008-02-11       Impact factor: 22.113

View more
  37 in total

1.  Contact activation of C3 enables tethering between activated platelets and polymorphonuclear leukocytes via CD11b/CD18.

Authors:  Osama A Hamad; Ioannis Mitroulis; Karin Fromell; Huda Kozarcanin; Triantafyllos Chavakis; Daniel Ricklin; John D Lambris; Kristina N Ekdahl; Bo Nilsson
Journal:  Thromb Haemost       Date:  2015-08-13       Impact factor: 5.249

Review 2.  Interactions between coagulation and complement--their role in inflammation.

Authors:  Katerina Oikonomopoulou; Daniel Ricklin; Peter A Ward; John D Lambris
Journal:  Semin Immunopathol       Date:  2011-08-03       Impact factor: 9.623

3.  Cutting edge: the membrane attack complex of complement is required for the development of murine experimental cerebral malaria.

Authors:  Theresa N Ramos; Meghan M Darley; Xianzhen Hu; Oliver Billker; Julian C Rayner; Malika Ahras; Jillian E Wohler; Scott R Barnum
Journal:  J Immunol       Date:  2011-05-13       Impact factor: 5.422

4.  Functional Relevance of the Anaphylatoxin Receptor C3aR for Platelet Function and Arterial Thrombus Formation Marks an Intersection Point Between Innate Immunity and Thrombosis.

Authors:  Reinhard J Sauter; Manuela Sauter; Edimara S Reis; Frederic N Emschermann; Henry Nording; Sonja Ebenhöch; Peter Kraft; Patrick Münzer; Maximilian Mauler; Johannes Rheinlaender; Johannes Madlung; Frank Edlich; Tilman E Schäffer; Sven G Meuth; Daniel Duerschmied; Tobias Geisler; Oliver Borst; Meinrad Gawaz; Christoph Kleinschnitz; John D Lambris; Harald F Langer
Journal:  Circulation       Date:  2018-10-16       Impact factor: 29.690

5.  Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis.

Authors:  Robert Silasi-Mansat; Hua Zhu; Narcis I Popescu; Glenn Peer; Georgia Sfyroera; Paola Magotti; Lacramioara Ivanciu; Cristina Lupu; Tom E Mollnes; Fletcher B Taylor; Gary Kinasewitz; John D Lambris; Florea Lupu
Journal:  Blood       Date:  2010-05-13       Impact factor: 22.113

Review 6.  The non-haemostatic role of platelets in systemic lupus erythematosus.

Authors:  Petrus Linge; Paul R Fortin; Christian Lood; Anders A Bengtsson; Eric Boilard
Journal:  Nat Rev Rheumatol       Date:  2018-03-21       Impact factor: 20.543

7.  Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles.

Authors:  Yvonne Klapper; Osama A Hamad; Yuji Teramura; Gero Leneweit; G Ulrich Nienhaus; Daniel Ricklin; John D Lambris; Kristina N Ekdahl; Bo Nilsson
Journal:  Biomaterials       Date:  2014-01-23       Impact factor: 12.479

8.  Contribution of chondroitin sulfate A to the binding of complement proteins to activated platelets.

Authors:  Osama A Hamad; Per H Nilsson; Maria Lasaosa; Daniel Ricklin; John D Lambris; Bo Nilsson; Kristina Nilsson Ekdahl
Journal:  PLoS One       Date:  2010-09-23       Impact factor: 3.240

9.  Identification of a novel mode of complement activation on stimulated platelets mediated by properdin and C3(H2O).

Authors:  Gurpanna Saggu; Claudio Cortes; Heather N Emch; Galia Ramirez; Randall G Worth; Viviana P Ferreira
Journal:  J Immunol       Date:  2013-05-15       Impact factor: 5.422

Review 10.  Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape.

Authors:  Dimitrios C Mastellos; Daniel Ricklin; Despina Yancopoulou; Antonio Risitano; John D Lambris
Journal:  Expert Rev Hematol       Date:  2014-09-02       Impact factor: 2.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.